Conditions: Chronic Hepatitis C (CHC)
Keywords: Pegasys
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 54
Healthy volunteers: no

Brief summary:
This study will evaluate the efficacy and safety of MP-424 with PEG-IFN Alfa-2a and RBV in patients with genotype 1 hepatitis C, who are naïve to its treatment or relapsed after previous treatment.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: MP-424 intervention 2: RBV intervention 3: PEG-IFN alfa-2a
Intervention descriptions: intervention 1: MP-424: 750mg every 8 hours (q8h) for 12 weeks intervention 2: RBV: 600 - 1000 mg/day based on body weight for 24 weeks intervention 3: PEG-IFN alfa-2a: 180mcg/week for 24 weeks

Protocol document: